Hospital
Allina Health System
Allina Health System was paid $4.23M by Medicaid between Jan 2018 and Dec 2024, across 82 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoALLINA HEALTH SYSTEM
NEW ULM, MN 56073
NEW ULM, MN 56073
33aNPI1558328435assigned 04/26/2006
33bProvider typeCritical Access Hospital
28Total paid$4.23M
24GClaims68,227
24DCodes billed82
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Minnesota
Rank by total paid#8 of 68
Median peer was paid$798K
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,609 | $162K | |
| 2019 | 11,251 | $638K | |
| 2020 | 8,721 | $455K | |
| 2021 | 14,399 | $771K | |
| 2022 | 13,597 | $896K | |
| 2023 | 10,353 | $750K | |
| 2024incomplete | 5,297 | $562K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 5,062 | 4,838 | $1.36M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 2,362 | 2,262 | $887K |
| 80053 | Comprehensive metabolic panel | 8.1% | 3,795 | 3,086 | $342K |
| H2035 | Alcohol and/or other drug treatment program, per hour | 5.6% | 3,061 | 569 | $236K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.9% | 2,554 | 2,489 | $208K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.8% | 401 | 387 | $203K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.2% | 1,573 | 1,432 | $134K |
| 36415 | Collection of venous blood by venipuncture | 3.0% | 15,023 | 13,361 | $126K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 3,795 | 3,065 | $113K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.8% | 367 | 360 | $76K |
| J3490 | Unclassified drugs | 1.6% | 10,397 | 4,935 | $69K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 640 | 620 | $50K |
70 more codes
| 85027 | <1% | 1,988 | $41K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,584 | $36K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 545 | $31K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,891 | $30K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 536 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 236 | $23K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,795 | $19K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 244 | $16K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 300 | $16K |
| 86140 | <1% | 682 | $15K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 94 | $15K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 13 | $14K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 961 | $12K |
| 81015 | <1% | 1,678 | $11K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 119 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 315 | $11K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 674 | $6K |
| 85018 | <1% | 776 | $6K | |
| 84512 | <1% | 125 | $6K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 39 | $5K |
| 86780 | <1% | 175 | $5K | |
| 73630 | <1% | 47 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 64 | $5K |
| 59025 | Fetal non-stress test | <1% | 17 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 92 | $4K |
| 83735 | <1% | 270 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 92 | $4K |
| 81001 | <1% | 334 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 27 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 198 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 58 | $3K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 13 | $3K |
| 85610 | <1% | 173 | $2K | |
| 83880 | <1% | 29 | $2K | |
| 84484 | <1% | 60 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 12 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 41 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 63 | $1K |
| 74018 | <1% | 12 | $1K | |
| 87081 | <1% | 124 | $1K | |
| 87150 | <1% | 12 | $1K | |
| 83605 | <1% | 51 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 36 | $1K |
| 86850 | <1% | 39 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 23 | $895.00 |
| 83655 | <1% | 70 | $835.47 | |
| 84145 | <1% | 13 | $770.85 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 15 | $747.59 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 22 | $683.73 |
| 11721 | <1% | 81 | $625.70 | |
| 81003 | <1% | 57 | $466.44 | |
| 80061 | Lipid panel | <1% | 12 | $432.06 |
| 86787 | <1% | 13 | $377.32 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12 | $359.95 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $350.93 |
| 86762 | <1% | 13 | $342.08 | |
| 84702 | <1% | 14 | $340.25 | |
| 86803 | <1% | 13 | $337.38 | |
| J2704 | Injection, propofol, 10 mg | <1% | 14 | $334.19 |
| 84100 | <1% | 30 | $320.72 | |
| 87340 | <1% | 13 | $312.86 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 31 | $305.94 |
| 86900 | <1% | 13 | $262.53 | |
| 86901 | <1% | 13 | $262.17 | |
| 81025 | <1% | 14 | $190.52 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16 | $152.86 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12 | $137.18 |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 12 | $134.27 |
| G0008 | Administration of influenza virus vaccine | <1% | 12 | $97.80 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 12 | $6.77 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFREIER, TOBY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Allina Health System | New Ulm, MN | $829K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.